Total Payments
$323,809
2024 Payments
$37,183
Companies
25
Transactions
147
Medicare Patients
5,624
Medicare Billing
$527,438
Payment Breakdown by Category
Other$187,500 (57.9%)
Consulting$90,475 (27.9%)
Research$34,999 (10.8%)
Food & Beverage$7,922 (2.4%)
Travel$2,650 (0.8%)
Gifts$262.66 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $187,500 | 9 | 57.9% |
| Consulting Fee | $90,475 | 30 | 27.9% |
| Unspecified | $34,999 | 22 | 10.8% |
| Food and Beverage | $7,922 | 74 | 2.4% |
| Travel and Lodging | $2,650 | 10 | 0.8% |
| Gift | $262.66 | 2 | 0.1% |
Payments by Type
General
$288,810
125 transactions
Research
$34,999
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch & Lomb, a division of Bausch Health US, LLC | $170,705 | 10 | $0 (2021) |
| F. Hoffmann-La Roche AG | $46,931 | 28 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $19,578 | 9 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $15,636 | 10 | $0 (2023) |
| EyePoint Pharmaceuticals US, Inc. | $14,597 | 18 | $0 (2024) |
| Novartis Pharma AG | $13,426 | 6 | $0 (2020) |
| Ocular Therapeutix, Inc. | $11,006 | 11 | $0 (2024) |
| Genentech, Inc. | $8,442 | 10 | $0 (2024) |
| Hexal AG | $6,323 | 7 | $0 (2020) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $5,726 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,183 | 27 | F. Hoffmann-La Roche AG ($19,846) |
| 2023 | $26,402 | 29 | F. Hoffmann-La Roche AG ($15,818) |
| 2022 | $22,281 | 24 | Bausch & Lomb Americas Inc. ($9,405) |
| 2021 | $13,547 | 11 | Genentech, Inc. ($6,396) |
| 2020 | $51,692 | 15 | Bausch & Lomb, a division of Bausch Health US, LLC ($22,063) |
| 2019 | $100,060 | 13 | Bausch & Lomb, a division of Bausch Health US, LLC ($97,053) |
| 2018 | $50,674 | 5 | Bausch & Lomb, a division of Bausch Health US, LLC ($50,089) |
| 2017 | $21,969 | 23 | Hexal AG ($5,848) |
All Payment Transactions
147 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Alcon Research LLC | AIR OPTIX (Device) | Food and Beverage | In-kind items and services | $148.36 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Gift | In-kind items and services | $142.46 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 10/18/2024 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $96.27 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $527.50 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 09/14/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $328.95 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 08/30/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $113.74 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 08/01/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Consulting Fee | Cash or cash equivalent | $5,775.00 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 07/18/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $66.65 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,175.00 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 06/28/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 06/23/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 06/23/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,330.00 | General |
| 05/07/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| 05/07/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 04/25/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 04/25/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,041.11 | Research |
| Study: Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $659.38 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 03/18/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $12,600.00 | General |
| 03/18/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $749.16 | General |
| 03/18/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $232.74 | General |
| 03/18/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $172.20 | General |
| 03/18/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $109.02 | General |
| 01/24/2024 | Genentech, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $60.39 | General |
| Category: Immunology and Ophthalmology | ||||||
| 01/19/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Publication support research related | Novartis Pharma AG | $9,514 | 3 |
| A PHASE II MULTICENTER, RANDOMIZED, ACTIVE TREATMENT-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $8,590 | 3 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $4,566 | 3 |
| A MULTI-MODAL DEEP LEARNING DL MODEL TO PREDICT VISUAL ACUITY RESPONSE IN THE CATT STUDY | F. Hoffmann-La Roche AG | $2,677 | 2 |
| VA2 PhIII Yosemite | F. Hoffmann-La Roche AG | $2,362 | 3 |
| Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes with DME in the YOSEMITE/RHINE Phase 3 Trials | F. Hoffmann-La Roche AG | $2,037 | 1 |
| Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials | F. Hoffmann-La Roche AG | $1,996 | 3 |
| Faricimab Personalised Treat-and-Extend-Based Dosing Dynamics in Patients With DME | F. Hoffmann-La Roche AG | $1,310 | 1 |
| Faricimab Personalized Treat-and-Extend-based Dosing Dynamics in Patients With DME | F. Hoffmann-La Roche AG | $841.47 | 1 |
| A MULTICENTER RANDOMIZED DOUBLE MASKED PHASE 3A STUDY TO ASSESS SAFETY AND EFFICACY OF BROLUCIZUMAB 6 MG Q4 WEEKS COMPARED TO AFLIBERCEPT 2 MG Q4 WEEKS IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION NAMD WITH PERSISTENT RETINAL FLUID | Novartis Pharmaceuticals Corporation | $750.00 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH BEOVU RESEARCH | Novartis Pharmaceuticals Corporation | $356.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,300 | 2,645 | $599,738 | $116,408 |
| 2022 | 9 | 1,359 | 2,783 | $658,562 | $129,887 |
| 2021 | 10 | 1,511 | 3,246 | $780,532 | $151,682 |
| 2020 | 10 | 1,454 | 2,799 | $678,555 | $129,461 |
Total Patients
5,624
Total Services
11,473
Medicare Billing
$527,438
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 396 | 853 | $248,223 | $70,538 | 28.4% |
| 92134 | Imaging of retina | Office | 2023 | 378 | 815 | $140,180 | $22,328 | 15.9% |
| 67028 | Injection of drug into eye | Facility | 2023 | 31 | 110 | $100,812 | $7,321 | 7.3% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 352 | 648 | $40,824 | $7,041 | 17.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 37 | 84 | $31,164 | $2,733 | 8.8% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 21 | 21 | $7,350 | $1,830 | 24.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 19 | 21 | $10,248 | $1,829 | 17.8% |
| 92250 | Photography of the retina | Office | 2023 | 52 | 69 | $13,041 | $1,725 | 13.2% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 14 | 24 | $7,896 | $1,063 | 13.5% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 424 | 926 | $269,466 | $78,822 | 29.3% |
| 92134 | Imaging of retina | Office | 2022 | 404 | 865 | $148,780 | $24,521 | 16.5% |
| 67028 | Injection of drug into eye | Facility | 2022 | 44 | 136 | $133,332 | $9,731 | 7.3% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 354 | 649 | $40,887 | $7,312 | 17.9% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2022 | 32 | 78 | $28,938 | $2,419 | 8.4% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 21 | 21 | $7,350 | $2,408 | 32.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 22 | 23 | $11,224 | $2,090 | 18.6% |
| 92250 | Photography of the retina | Office | 2022 | 45 | 67 | $12,663 | $1,790 | 14.1% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 13 | 18 | $5,922 | $795.29 | 13.4% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 453 | 1,018 | $296,238 | $87,129 | 29.4% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 425 | 1,025 | $176,300 | $29,280 | 16.6% |
| 67028 | Injection of drug into eye | Facility | 2021 | 52 | 188 | $177,234 | $13,332 | 7.5% |
| 92202 | Extended examination of eye with drawing of optic nerve and surrounding area (macula) | Office | 2021 | 386 | 744 | $46,872 | $8,347 | 17.8% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 36 | 36 | $12,600 | $3,814 | 30.3% |
| 92235 | Imaging of blood vessels in back of eye using fluorescein dye | Office | 2021 | 37 | 42 | $20,496 | $3,582 | 17.5% |
| 92250 | Photography of the retina | Office | 2021 | 72 | 99 | $18,711 | $2,791 | 14.9% |
About Dr. Glenn Jaffe, M.D
Dr. Glenn Jaffe, M.D is a Ophthalmology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255415311.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Glenn Jaffe, M.D has received a total of $323,809 in payments from pharmaceutical and medical device companies, with $37,183 received in 2024. These payments were reported across 147 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($187,500).
As a Medicare-enrolled provider, Jaffe has provided services to 5,624 Medicare beneficiaries, totaling 11,473 services with total Medicare billing of $527,438. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Durham, NC
- Active Since 10/25/2006
- Last Updated 08/22/2013
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1255415311
Products in Payments
- STELLARIS (Device) $134,000
- VISUDYNE (Drug) $20,063
- RETISERT (Drug) $20,000
- EYLEA (Biological) $16,632
- Lucentis (Biological) $12,928
- BLZ_BEOVU_OPHTHALMOLOGY (Drug) $9,514
- YUTIQ (Drug) $8,679
- STELLARIS ELITE (Device) $7,500
- EYP-1901 (Drug) $5,917
- BEOVU (Drug) $5,695
- RTH258A (Drug) $3,912
- KEVZARA SARILUMAB INJECTION (Biological) $3,066
- Spectralis (Device) $2,663
- XIPERE (Drug) $1,771
- MK-8931 (Drug) $1,125
- DEXTENZA (Drug) $676.34
- Humira (Biological) $500.00
- STELLARIS PC (Device) $254.13
- Vabysmo (Drug) $247.92
- OZURDEX (Drug) $223.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Durham
Julie Woodward, Md, MD
Ophthalmology — Payments: $1.1M
Ophthalmology $1.1M
Terry Kim, M.d, M.D
Ophthalmology — Payments: $955,773
Ophthalmology $955,773
Dr. Lejla Vajzovic, M.d, M.D
Ophthalmology — Payments: $645,013
Ophthalmology $645,013
Dr. Robin Vann, M.d, M.D
Ophthalmology — Payments: $281,269
Ophthalmology $281,269
Dr. Victor Perez Quinones, Md, MD
Ophthalmology — Payments: $271,372
Ophthalmology $271,372
Leon Herndon, M.d, M.D
Ophthalmology — Payments: $202,972
Ophthalmology $202,972